Survodutide

Last Updated: August 2026

Survodutide (BI 456906) is an investigational dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. It is in Phase 3 clinical development for obesity (SYNCHRONIZE program) and metabolic dysfunction-associated steatohepatitis (MASH); the first Phase 3 obesity results (SYNCHRONIZE-1) were published in the New England Journal of Medicine in June 2026, on top of the published Phase 2 hepatic and weight-loss data.1 source Survodutide is not approved for any indication as of August 2026 and is sold as a research-use-only compound by third-party laboratories.

What is survodutide and how does the GLP-1/glucagon dual mechanism work?

Survodutide activates both GLP-1 and glucagon receptors with a single peptide — a 29-amino-acid backbone structurally modified from glucagon, acylated with a C18 fatty diacid — combining GLP-1-mediated appetite suppression with glucagon-mediated direct energy expenditure and hepatic fat clearance.2 sources The survodutide dual GLP-1/glucagon science guide covers the receptor pharmacology in depth. The glucagon component is the differentiating mechanism — the same axis exploited by retatrutide (triple) and mazdutide (the other Phase 3 dual GLP-1/glucagon, China-led). Half-life is approximately 7 days, enabling once-weekly subcutaneous dosing. Evidence level: Human RCT (Phase 2 and Phase 3 published; further Phase 3 trials ongoing).

What does the clinical evidence show for survodutide?

In the Phase 2 dose-finding obesity trial (n=387), survodutide produced 14.9% average weight loss at the 4.8 mg dose over 46 weeks on the planned-treatment analysis (versus 2.8% with placebo) in adults with overweight or obesity; participants who reached and maintained the 4.8 mg dose lost up to 18.7%.1 source In the Phase 2 MASH trial (n=293, 48 weeks), up to 62% of participants on survodutide achieved improvement in MASH without worsening of fibrosis versus 14% on placebo, and up to 67% achieved at least a 30% reduction in liver fat content.1 source A Phase 3 trial in obesity with MASLD (SYNCHRONIZE-MASLD), published in Nature Medicine in 2026, reported that 84.2% of survodutide-treated participants achieved at least a 30% reduction in liver-fat content versus 24.3% on placebo (mean liver-fat change −12.2% vs −1.0%).1 source The Phase 3 readout has since arrived. In SYNCHRONIZE-1 (n=725, 76 weeks; published in the New England Journal of Medicine, June 2026), survodutide produced 12.2% (3.6 mg) and 13.0% (6.0 mg) average weight loss versus 5.4% with placebo on the published primary (treatment-regimen) estimand — and 15.3%/16.6% versus 3.2% on the efficacy estimand (participants adhering to treatment); 28.5% of the 6.0-mg group lost at least 20% of body weight versus 6.6% on placebo.1 source SYNCHRONIZE-2, in people with obesity and type 2 diabetes, is due to be presented at the EASD annual meeting, and results from the SYNCHRONIZE-CVOT cardiovascular outcomes trial are expected later in 2026.1 source Evidence level: Human RCT (Phase 2 and Phase 3 published).

How does survodutide compare to retatrutide and other dual agonists?

Survodutide and mazdutide share the GLP-1/glucagon dual mechanism but are developed by different sponsors targeting different lead markets — survodutide US/global via Boehringer Ingelheim, mazdutide China-led via Innovent Biologics. Retatrutide adds GIP to that mechanism, producing larger weight-loss signals at the cost of more complex synthesis.

A third GLP-1/glucagon dual agonist, pemvidutide (Altimmune), entered Phase 3 for MASH in August 2026.1 source For a structured dual-vs-triple comparison, see retatrutide vs survodutide vs mazdutide.

What are the documented side effects of survodutide?

The most common survodutide side effects in Phase 2 were gastrointestinal — nausea, vomiting, decreased appetite — generally mild-to-moderate and concentrated in dose escalation, with discontinuation rates comparable to other GLP-1-class compounds. The glucagon component raises theoretical concerns about heart rate increases that the ongoing Phase 3 program — including the SYNCHRONIZE-CVOT cardiovascular outcomes trial — will further characterize. Long-term safety data is more limited than for FDA-approved alternatives. Evidence level: Human RCT (Phase 2 and Phase 3).

What is the regulatory status of survodutide?

Survodutide is not approved by the FDA, EMA, or any other regulator as of August 2026, and no regulatory submission has been announced. The registrational picture is maturing: SYNCHRONIZE-1 (obesity) is published, SYNCHRONIZE-2 (obesity with type 2 diabetes) is due for presentation at the EASD annual meeting, SYNCHRONIZE-CVOT results are expected later in 2026, and Boehringer Ingelheim has announced four additional Phase 3(b) trials starting in 2026.1 source In MASH, survodutide holds FDA Breakthrough Therapy designation (granted October 2024 for non-cirrhotic MASH with moderate or advanced fibrosis) and is in two Phase 3 trials — LIVERAGE (~1,800 adults with stage 2–3 fibrosis) and LIVERAGE-Cirrhosis (~1,590 adults with compensated cirrhosis).1 source Regulatory context in FDA peptide regulation 2025–2026 timeline.

Why does survodutide vendor verification matter?

Survodutide is among the newer investigational GLP-1/glucagon agonists with a narrower manufacturing base than semaglutide or tirzepatide, creating wider purity variance and stronger economic incentive for underdosing. Independent HPLC purity testing and mass spectrometry identity confirmation are the only meaningful purity signals. Some vendors mislabel survodutide as a generic "GLP-1/glucagon dual agonist" without specifying BI 456906; buyers should confirm the specific compound. Guidance in our how-to-test-peptides hub.

How does Peptigrity verify survodutide vendors?

Peptigrity collects independent third-party Certificates of Analysis for survodutide from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. The lab test table above this section shows the cross-shop dataset for what's been tested. Methodology in how we calculate trust scores.

Frequently Asked Questions

How can I verify a survodutide vendor is selling real product?

The only reliable purity signal is an independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay — and for survodutide specifically, buyers should verify the compound is labeled correctly (BI 456906), not as a generic "GLP-1/glucagon dual agonist" that could be mazdutide or another molecule. Compare vendors against the independent survodutide lab tests on file. For COA interpretation, see red flags in peptide certificates of analysis.

Is survodutide legal to purchase?

Survodutide is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption. Buyers are responsible for verifying local import rules — full breakdown in peptide legal status guide.

When will survodutide be FDA-approved?

No FDA approval has been granted as of August 2026, and Boehringer Ingelheim has not announced a regulatory filing. The first Phase 3 obesity trial (SYNCHRONIZE-1) is now published, with SYNCHRONIZE-2 and cardiovascular-outcomes results expected through late 2026 — an approval decision, if the program succeeds, would follow a future submission whose date has not been announced.2 sources In MASH, survodutide holds FDA Breakthrough Therapy designation. Track developments in FDA peptide regulation 2025–2026 timeline.

Is survodutide different from mazdutide?

Yes. Both are dual GLP-1/glucagon receptor agonists with similar mechanism logic but they are different molecules from different sponsors — survodutide (BI 456906) from Boehringer Ingelheim, mazdutide (IBI362) from Innovent Biologics. They are not interchangeable. The regulatory gap is now concrete: mazdutide was approved in China in June 2025 for chronic weight management (brand Xinermei®) and in September 2025 for type 2 diabetes, while survodutide is not yet approved anywhere.1 source

Does Peptigrity recommend a survodutide dose?

No. Survodutide is not approved for human consumption and Peptigrity is an independent review platform, not a medical authority. The doses studied in Phase 2 (0.6 mg through 4.8 mg weekly) were administered under clinical supervision. Anyone considering investigational compound use should consult a licensed physician.

What is the MASH connection with survodutide?

Survodutide has produced strong Phase 2 data in MASH (metabolic dysfunction-associated steatohepatitis): up to 62% of treated participants achieved improvement in MASH without worsening of fibrosis versus 14% on placebo, and up to 67% achieved at least a 30% reduction in liver fat content.1 source The FDA granted Breakthrough Therapy designation for non-cirrhotic MASH in October 2024, and the Phase 3 LIVERAGE trials are ongoing.1 source and histological improvement in MASH resolution. The glucagon mechanism is mechanistically suited to hepatic fat clearance — a differentiator from GLP-1-only compounds. A dedicated MASH Phase 3 program is running in parallel with the obesity program.

This section is for educational and informational purposes only and does not constitute medical advice. Survodutide is an investigational compound not approved by the FDA or any other regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.